【摘 要】拉米夫定治疗慢性乙型肝炎期间会出现耐药及HBV- YMDD变异，治疗持续时间短，患者不易接受。阿德福韦酯是被国家食品药品监督管理局(SFDA)批准用于抗乙型肝炎病毒(HBV)的第二个核苷类似物，能有效抑制HBVDNA的复制，且病毒变异率低。笔者根据相关资料就阿德福韦酯的研究现状及临床观察作一总结，使临床医生和患者对新核苷类药物治疗乙肝的合理性和安全性有更深刻的了解。

    【关键词】阿德福韦酯；研究进展

    【中图分类号】R 969 【文献标识码】A 【文章编号】1004- 7484(2012)05- 0276- 01

    【adstract】the Lami husband decides treatment chromic hepatitis B period will appear bear the medicine and HBV-YMDD the variation,the treatment duration is short,the patient will not be easy to accept.Arab League German luck Wei Zhi is(SFDA)is authorized by the national food Drugs Surveillance Administrative bureau to use in the anti-hepatitis B virus (HBV)the second nuclear glucoside synonym,can suppress HBV DNA effectively the duplication, and the viral variation rate is low.The author acts according to the correlation data makes a summary on the Arad League German luck Wei Zhi research present situation and the clinical observation, causes clinician and the patient pharmacological treatment hepatitis B’s rationality and the security to new nuclear glucoside class has a more profound understanding. ......